Human hendra virus and nipah virus antibodies and methods of use therefor
AssigneeVanderbilt University
InventorJames E. Crowe, Jr.
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to antibodies binding to and neutralizing henipavirus and methods for use thereof. Thus, in accordance with the present disclosure, there is provided a method of detecting a henipavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively; and (b) detecting henipavirus in said sample by binding of said antibody or antibody fragment to a henipavirus antigen in said sample.
Claims18
A method of treating a subject infected with henipavirus, or reducing the likelihood of infection of a subject at risk of contracting henipavirus, comprising delivering to said subject an antibody or antibody fragment comprising heavy and light chain Complementarity Determining Regions 1-3, respectively, selected from:
- SEQ ID NOS:
- 97-99 and 172-174, respectively;
- SEQ ID NOS:
- 100-102 and 175-177, respectively;
- SEQ ID NOS:
- 103-105 and 178-180, respectively;
- SEQ ID NOS:
- 106-108 and 181-183, respectively;
- SEQ ID NOS:
- 109-111 and 184-186, respectively;
- SEQ ID NOS:
- 115-117 and 187-189, respectively;
- SEQ ID NOS:
- 118-120 and 190-192, respectively;
- SEQ ID NOS:
- 121-123 and 193-195, respectively;
- SEQ ID NOS:
- 124-126 and 196-198, respectively;
- SEQ ID NOS:
- 130-132 and 199-201, respectively;
- SEQ ID NOS:
- 133-135 and 202-204, respectively;
- SEQ ID NOS:
- 136-138 and 205-207, respectively;
- SEQ ID NOS:
- 139-141 and 208-210, respectively;
- SEQ ID NOS:
- 142-144 and 211-213, respectively;
- SEQ ID NOS:
- 145-147 and 214-216, respectively;
- SEQ ID NOS:
- 148-150 and 217-219, respectively;
- SEQ ID NOS:
- 151-153 and 220-222, respectively;
- SEQ ID NOS:
- 154-156 and 223-225, respectively;
- SEQ ID NOS:
- 157-159 and 226-228, respectively;
- SEQ ID NOS:
- 160-162 and 229-231, respectively;
- SEQ ID NOS:
- 163-165 and 232-234, respectively;
- SEQ ID NOS:
- 166-168 and 235-237, respectively;
- or SEQ ID NOS:
- 169-171 and 238-240, respectively.
A monoclonal antibody or antibody fragment comprising heavy and light chain Complementarity Determining Regions 1-3, respectively, selected from:
- SEQ ID NOS:
- 97-99 and 172-174, respectively;
- SEQ ID NOS:
- 100-102 and 175-177, respectively;
- SEQ ID NOS:
- 103-105 and 178-180, respectively;
- SEQ ID NOS:
- 106-108 and 181-183, respectively;
- SEQ ID NOS:
- 109-111 and 184-186, respectively;
- SEQ ID NOS:
- 115-117 and 187-189, respectively;
- SEQ ID NOS:
- 118-120 and 190-192, respectively;
- SEQ ID NOS:
- 121-123 and 193-195, respectively;
- SEQ ID NOS:
- 124-126 and 196-198, respectively;
- SEQ ID NOS:
- 130-132 and 199-201, respectively;
- SEQ ID NOS:
- 133-135 and 202-204, respectively;
- SEQ ID NOS:
- 136-138 and 205-207, respectively;
- SEQ ID NOS:
- 139-141 and 208-210, respectively;
- SEQ ID NOS:
- 142-144 and 211-213, respectively;
- SEQ ID NOS:
- 145-147 and 214-216, respectively;
- SEQ ID NOS:
- 148-150 and 217-219, respectively;
- SEQ ID NOS:
- 151-153 and 220-222, respectively;
- SEQ ID NOS:
- 154-156 and 223-225, respectively;
- SEQ ID NOS:
- 157-159 and 226-228, respectively;
- SEQ ID NOS:
- 160-162 and 229-231, respectively;
- SEQ ID NOS:
- 163-165 and 232-234, respectively;
- SEQ ID NOS:
- 166-168 and 235-237, respectively;
- or SEQ ID NOS:
- 169-171 and 238-240, respectively, wherein said antibody is an IgG, or a recombinant IgG antibody or antibody fragment comprising an Fc portion mutated to eliminate or enhance FcR interactions, to increase half-life and/or increase therapeutic efficacy, or glycan modified to eliminate or enhance FcR interactions.
A hybridoma or engineered cell expressing an antibody or antibody fragment comprising heavy and light chain Complementarity Determining Regions 1-3, respectively, selected from:
- SEQ ID NOS:
- 97-99 and 172-174, respectively;
- SEQ ID NOS:
- 100-102 and 175-177, respectively;
- SEQ ID NOS:
- 103-105 and 178-180, respectively;
- SEQ ID NOS:
- 106-108 and 181-183, respectively;
- SEQ ID NOS:
- 109-111 and 184-186, respectively;
- SEQ ID NOS:
- 115-117 and 187-189, respectively;
- SEQ ID NOS:
- 118-120 and 190-192, respectively;
- SEQ ID NOS:
- 121-123 and 193-195, respectively;
- SEQ ID NOS:
- 124-126 and 196-198, respectively;
- SEQ ID NOS:
- 130-132 and 199-201, respectively;
- SEQ ID NOS:
- 133-135 and 202-204, respectively;
- SEQ ID NOS:
- 136-138 and 205-207, respectively;
- SEQ ID NOS:
- 139-141 and 208-210, respectively;
- SEQ ID NOS:
- 142-144 and 211-213, respectively;
- SEQ ID NOS:
- 145-147 and 214-216, respectively;
- SEQ ID NOS:
- 148-150 and 217-219, respectively;
- SEQ ID NOS:
- 151-153 and 220-222, respectively;
- SEQ ID NOS:
- 154-156 and 223-225, respectively;
- SEQ ID NOS:
- 157-159 and 226-228, respectively;
- SEQ ID NOS:
- 160-162 and 229-231, respectively;
- SEQ ID NOS:
- 163-165 and 232-234, respectively;
- SEQ ID NOS:
- 166-168 and 235-237, respectively;
- or SEQ ID NOS:
- 169-171 and 238-240, respectively.
A vaccine formulation comprising one or more antibodies or antibody fragments comprising heavy and light chain Complementarity Determining Regions 1-3, respectively, of:
- SEQ ID NOS:
- 97-99 and 172-174, respectively;
- SEQ ID NOS:
- 100-102 and 175-177, respectively;
- SEQ ID NOS:
- 103-105 and 178-180, respectively;
- SEQ ID NOS:
- 106-108 and 181-183, respectively;
- SEQ ID NOS:
- 109-111 and 184-186, respectively;
- SEQ ID NOS:
- 115-117 and 187-189, respectively;
- SEQ ID NOS:
- 118-120 and 190-192, respectively;
- SEQ ID NOS:
- 121-123 and 193-195, respectively;
- SEQ ID NOS:
- 124-126 and 196-198, respectively;
- SEQ ID NOS:
- 130-132 and 199-201, respectively;
- SEQ ID NOS:
- 133-135 and 202-204, respectively;
- SEQ ID NOS:
- 136-138 and 205-207, respectively;
- SEQ ID NOS:
- 139-141 and 208-210, respectively;
- SEQ ID NOS:
- 142-144 and 211-213, respectively;
- SEQ ID NOS:
- 145-147 and 214-216, respectively;
- SEQ ID NOS:
- 148-150 and 217-219, respectively;
- SEQ ID NOS:
- 151-153 and 220-222, respectively;
- SEQ ID NOS:
- 154-156 and 223-225, respectively;
- SEQ ID NOS:
- 157-159 and 226-228, respectively;
- SEQ ID NOS:
- 160-162 and 229-231, respectively;
- SEQ ID NOS:
- 163-165 and 232-234, respectively;
- SEQ ID NOS:
- 166-168 and 235-237, respectively;
- or SEQ ID NOS:
- 169-171 and 238-240, respectively.
Dependencies are inferred from the claim text.